STUDY OF THE QUANTITATIVE CONTENT OF THE MAIN GROUPS OF BIOLOGICALLY ACTIVE SUBSTANCES IN COMBINED PHYTOCOMPLEXES BASED ON VITEX AGNUS CASTUS
DOI:
https://doi.org/10.32782/health-2025.3.13Keywords:
phytocomplex, herbal medicine, chasteberry (Vitex agnus-castus), quantitative content, UV spectrophotometry, female reproductive health, hormonal balanceAbstract
The aim of the work. A comparative study of the quantitative content of the main groups of biologically active substances in phytocomplexes of different manufacturers represented on the domestic pharmaceutical market based on Vitex agnus-castus for normalization of the functional state of the female reproductive organs.For the study, herbal remedies from different manufacturers represented on the pharmaceutical market of Ukraine were selected, namely: Normomens capsules (Prakruti Products Pvt Ltd, India), Mastodinon tablets (Bionorica SE, Germany), Femimens capsules (Ananta Medicare Ltd, India), and Cyclotime capsules (Nutrimed LLC, Ukraine).Quantitative determination of the main groups of biologically active substances was performed by UV spectrophotometry using a LABAnalyt SP-V1000 spectrophotometer (China). The amount of iridoid glycosides (aucubin equivalent), the amount of phenolic compounds (gallic acid equivalent), the amount of flavonoids (rutin equivalent) and the amount of hydroxycinnamic acids (chlorogenic acid equivalent) were determined in the studied phytocomplexes.The phytocomplex Mastodynon contained all the studied classes of BAS in trace amounts. A comparative analysis of the total content of iridoid glycosides in 1 dose of the product showed that Normomens contains 27% more iridoids than Cyclotime and over 1.5 times more than Femimens. In terms of the sum of phenolic compounds, the results of Normomens and Cyclotime were almost at the same level, but both were superior to Femimens. Cyclotime contained the highest amount of flavonoids – almost 15% more than Normomens and nearly 27% more than Femimens. Regarding the amount of hydroxycinnamic acids, Cyclotime also outperformed the other objects: by 19% – Femimens and by 29% – Normomens. When analyzing the results obtained, it should be borne in mind that for this group of phytocomplexes, taking into account the indications for use, the most priority class of BAS is iridoids.Considering the quantitative content of total bioactive compounds (especially iridoids), Normomens, in terms of a single dose of the herbal remedy, is capable of providing a higher level of active components responsible for biological activity compared to Cyclotime, Femimens, and Mastodinon.
References
Kenda M., Glavač N.K., Nagy M., Sollner Dolenc M. Herbal products used in menopause and for gynecological disorders. Molecules. 2021. Vol. 26, № 24. P. 7421. DOI: https://doi.org/10.3390/molecules26247421
Bernardi M., Lazzeri L., Perelli F. et al. Dysmenorrhea and related disorders. F1000Research. 2017. Vol. 6. P. 1645. DOI: https://doi.org/10.12688/f1000research.11682.1
Cheema D., Coomarasamy A., El-Toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: A structured evidence-based review. Archives of Gynecology and Obstetrics. 2007. Vol. 276. P. 463–469. DOI: https://doi.org/10.1007/s00404-007-0371-9
Handley A.P., Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: A systematic review. Journal of the American Association of Nurse Practitioners. 2015. Vol. 27. P. 54–61. DOI: https://doi.org/10.1002/2327-6924.12119
Oh M.R., Park J.H., Park S.K., Park S.H. Efficacy of plant-derived dietary supplements in improving overall menopausal symptoms in women: An updated systematic review and meta-analysis. Phytotherapy Research. 2024. Vol. 38, № 3. P. 1294–1309. DOI: https://doi.org/10.1002/ptr.8112
Marjoribanks J., Farquhar C., Roberts H. et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews. 2017. № 7. CD004143. DOI: https://doi.org/10.1002/14651858. CD004143.pub5
Дієтичні добавки для зниження ризику функціональних порушень жіночих циклічних процесів. URL: https://compendium.com.ua/uk/bad/0007000b0002/
Rani A., Sharma A. The genus Vitex: A review. Pharmacognosy Reviews. 2013. Vol. 7. P. 188. DOI: https://doi. org/10.4103/0973-7847.120524
Köngül E. Agnus Castus. Nonvitamin and Nonmineral Nutritional Supplements. 1st ed. Amsterdam: Elsevier, 2019. P. 139–143. DOI: https://doi.org/10.1016/B978-0-12-812491-8.00022-0
Niroumand M.C., Heydarpour F., Farzaei M.H. Pharmacological and therapeutic effects of Vitex agnus-castus L.: A review. Pharmacognosy Reviews. 2018. Vol. 12. P. 103–114. DOI: https://doi.org/10.4103/phrev.phrev_22_18
Girman A., Lee R., Kligler B. An integrative medicine approach to premenstrual syndrome. American Journal of Obstetrics and Gynecology. 2003. Vol. 188. P. S56–S65. DOI: https://doi.org/10.1067/mob.2003.500
Lauritzen C., Reuter H.D., Repges R. et al. Treatment of premenstrual tension syndrome with Vitex agnus castus: Controlled, double-blind study versus pyridoxine. Phytomedicine. 1997. Vol. 4. P. 183–189. DOI: https://doi.org/10.1016/S0944-7113(97)80008-9
Berger D., Schaffner W., Schrader E. et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre- menstrual syndrome (PMS). Archives of Gynecology and Obstetrics. 2000. Vol. 264. P. 150–153. DOI: https://doi.org/10.1007/s004040000123
Halaska M., Beles P., Gorkow C., Sieder C. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: Results of a placebo-controlled double-blind study. Breast. 1999. Vol. 8. P. 175–181. DOI: https://doi.org/10.1054/brst.1999.0039
Csupor D., Lantos T., Hegyi P. et al. Vitex agnus-castus in premenstrual syndrome: A meta-analysis of double-blind randomised controlled trials. Complementary Therapies in Medicine. 2019. Vol. 47. P. 102190. DOI: https://doi.org/10.1016/j. ctim.2019.102190
Neghab N., Zamani M., Torabian S. Therapeutic Effect of Vitex Agnus Castus in Patients with Premenstrual Syndrome. Acta Medica Iranica. 2012. Vol. 50. P. 101–106. DOI: https://doi.org/10.18502/acta.v50i2.4150
Milewicz A., Gejdel E., Sworen H. et al. Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia: Results of a randomized placebo-controlled double-blind study. Arzneimittelforschung. 1993. Vol. 43. P. 752–756. DOI: https://doi.org/10.1055/s-0031-1309949
Kilicdag E.B., Tarim E., Bagis T. et al. Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia. International Journal of Gynecology & Obstetrics. 2004. Vol. 85. P. 292–293. DOI: https://doi.org/10.1016/j. ijgo.2003.10.018
Gerhard I., Patek A., Monga B. et al. Mastodynon® bei weiblicher Sterilität. Complementary Medicine Research. 1998. Vol. 5. P. 272–278. DOI: https://doi.org/10.1159/000021324
Kırmızıbekmez H., Demir D. Iridoid Glycosides and Phenolic Compounds from the Flowers of Vitex agnus-castus. Helvetica Chimica Acta. 2016. Vol. 99. P. 518–522. DOI: https://doi.org/10.1002/hlca.201500222
Zahid H., Rizwani G.H., Ishaqe S. Phytopharmacological review on Vitex agnus-castus: A potential medicinal plant. Chinese Herbal Medicine. 2016. Vol. 8. P. 24–29. DOI: https://doi.org/10.1016/S1674-6384(16)60005-0
Puglia L.T., Lowry J., Tamagno G. Vitex agnus castus effects on hyperprolactinaemia. Frontiers in Endocrinology (Lausanne). 2023. Vol. 14. P. 1269781. DOI: https://doi.org/10.3389/fendo.2023.1269781
Sliutz G., Speiser P., Schultz A.M. et al. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Hormone and Metabolic Research. 1993. Vol. 25, № 5. P. 253–255. DOI: https://doi.org/10.1055/s-2007-1002090
Roemhed-Hamm B. Chasteberry. American Family Physician. 2005. Vol. 72, № 5. P. 821–824.
European Medicines Agency (EMA); Committee on Herbal Medicinal Products (HMPC). Assessment Report on Trigonella foenum-graecum L., Semen. EMA/HMPC/146220/2010. Amsterdam: EMA, 2010. Vol. 44. P. 1–42.
Bhat K.M.R., Nagamma T., Konuri A. Medicinal value of Phytoestrogens in Trigonella foenum-graecum L. (Fenugreek) – Review. Biomedical and Pharmacology Journal. 2023. Vol. 16, № 4. DOI: https://doi.org/10.13005/bpj/2768
Nagulapalli Venkata K. C., Swaroop A., Bagchi D., Bishayee A. A small plant with big benefits: Fenugreek (Trigonella foenumgraecum Linn.) for disease prevention and health promotion. Molecular Nutrition & Food Research. 2017. Vol. 61. P. 1600950. DOI: https://doi.org/10.1002/mnfr.201600950
Rao A., Steels E., Beccaria G. et al. Influence of a specialized Trigonella foenum-graecum seed extract (Libifem) on testosterone, estradiol and sexual function in healthy menstruating women: A randomised placebo-controlled study. Phytotherapy Research. 2015. Vol. 29. P. 1123–1130. DOI: https://doi.org/10.1002/ptr.5346
Hakimi S., Mohammad Alizadeh S., Delazar A. et al. Probable Effects of Fenugreek Seed on Hot Flash in Menopausal Women. Journal of Medicinal Plants. 2006. Vol. 5. P. 9–14.
Khanna A., John F., Das S. et al. Efficacy of a novel extract of fenugreek seeds in alleviating vasomotor symptoms and depression in perimenopausal women: A randomized, double-blinded, placebo-controlled study. Journal of Food Biochemistry. 2020. Vol. 44. e13507. DOI: https://doi.org/10.1111/jfbc.13507
Thomas J.V., Rao J., John F. et al. Phytoestrogenic effect of fenugreek seed extract helps in ameliorating the leg pain and vasomotor symptoms in postmenopausal women: A randomized, double-blinded, placebo-controlled study. PharmaNutrition. 2020. Vol. 14. P. 100209. DOI: https://doi.org/10.1016/j.phanu.2020.100209
Grzanna R., Lindmark L., Frondoza C.G. Ginger – an herbal medicinal product with broad anti-inflammatory actions. Journal of Medicinal Food. 2005. Vol. 8, № 2. P. 125–132. DOI: https://doi.org/10.1089/jmf.2005.8.125
Commisso M., Bianconi M., Poletti S. et al. Metabolomic Profiling and Antioxidant Activity of Fruits Representing Diverse Apple and Pear Cultivars. Biology (Basel). 2021. Vol. 10, № 5. P. 380. DOI: https://doi.org/10.3390/biology10050380
Levine S., Muneyyirci-Delale O. Stress-Induced Hyperprolactinemia: Pathophysiology and Clinical Approach. Obstetrics and Gynecology International. 2018. P. 9253083. DOI: https://doi.org/10.1155/2018/9253083
Gopal S., Ajgaonkar A., Kanchi P. et al. Effect of an ashwagandha (Withania Somnifera) root extract on climacteric symptoms in women during perimenopause: A randomized, double-blind, placebo-controlled study. The journal of obstetrics and gynaecology research. 2021. Vol. 47, № 12. P. 4414–4425. DOI: https://doi.org/10.1111/jog.15030
Kim M.Y., Choi S.D., Ryu A. Is complementary and alternative therapy effective for women in the climacteric period?. Journal of Menopausal Medicine. 2015. Vol. 21, № 1. P. 28–35. DOI: https://doi.org/10.6118/jmm.2015.21.1.28
Державна Фармакопея України : у 3-х т. / ДП «Український науковий фармакопейний центр якості лікарських засобів». 2-е вид. Харків, 2015. Т. 1. 1128 с.
Маслов О.Ю. Фітохімічне вивчення та стандартизація лікарських засобів антиоксидантної дії з листя зеленого чаю : дис. ... докт. філософії : 226. Харків, 2022. 200 с.
Дослідження іридоїдів вітексу священного (Vitex agnus-castus L.) та вітексу коноплевидного (Vitex cannabifolia Sieb.) / О.О. Цуркан та ін. Фармацевтичний журнал. 2014. № 2. С. 101–104.
